Bridging the Gap

African Americans are 3 to 4 times more likely to develop kidney failure, which has raised the possibility of a genetic cause for this disparity.^{1, 2} Research has discovered hundreds of genes linked to increased risk for kidney disease, including the APOL1 gene – thought to be associated with a rapidly progressive form of chronic kidney disease for people of African ancestry who have high risk variants. Genetic testing is the first step for patients to understand their genetic risk and better inform their treatment options.

Vertex Pharmaceuticals is sponsoring a no-cost testing program to provide Renasight™ genetic test to eligible* individuals who have been diagnosed with non-diabetic chronic kidney disease.